Intangible Assets

PULM appears to rely on patent- and regulatory-protected respiratory drug assets rather than broad brand power, but its small commercial footprint limits peer-level pricing leverage versus larger specialty pharma peers.

Any intangible value is concentrated in a narrow product set, so durability depends on continued exclusivity and clinical differentiation rather than a diversified portfolio that would sustain margins for 5–10 years.

Compared with larger peers that can spread R&D and commercialization across multiple assets, PULM’s intangible assets are less likely to translate into durable, above-peer pricing power if a key product loses protection or relevance.

Switching Costs

PULM does not appear to benefit from meaningful customer lock-in because prescribing decisions in its markets are typically driven by clinical preference, payer access, and formulary status rather than embedded workflow dependence.

Compared with peers that sell chronic therapies with established patient persistence or platform-based products, PULM’s switching costs are low because patients and prescribers can move to alternatives when coverage or efficacy changes.

The company’s negative profitability metrics indicate limited evidence that any switching friction is strong enough to protect retention or margins versus peers.

Network Effects

PULM does not exhibit a meaningful network effect because demand for its products is not strengthened by user-to-user adoption, data accumulation, or ecosystem participation.

Unlike platform or diagnostic peers where scale can improve product utility or market access, PULM’s value proposition is product-specific and does not compound through a network.

Cost Advantage

PULM shows no clear cost advantage because its TTM ROIC is deeply negative, which suggests it is not converting capital into returns more efficiently than peers.

A small operating base can sometimes lower overhead, but there is no evidence here of manufacturing, procurement, or distribution scale that would structurally undercut larger competitors.

Compared with established pharma peers that can leverage scale in development, commercialization, and supply chain, PULM appears cost-disadvantaged rather than cost-leading.

Efficient Scale

PULM operates in a niche where market size may limit the number of viable competitors, but the available evidence does not show that this niche is large enough to create durable efficient-scale protection.

Compared with peers that dominate a specialized channel or infrastructure layer, PULM lacks signs of industry dependency or capacity constraints that would prevent entry and preserve margins.

The absence of strong profitability and the lack of visible scale economics suggest efficient scale is not yet a durable moat driver versus peers.

Overall Score

PULM’s moat is weak versus peers because its advantage appears limited to narrow, product-level exclusivity with low switching costs, no network effects, and no demonstrated cost or scale advantage; the negative TTM ROIC further suggests these structural features are not yet supporting durable pricing power or retention.